Marvin Seife plea
Former FDA Generic Drugs Division Director Seife pleads not guilty to two counts of perjury at June 29 arraignment in Baltimore federal court. The two-count indictment alleges that Seife lied to an FDA investigator and Rep. Dingell's (D-Mich.) House Energy and Commerce/Oversight Subcommittee about having lunch with two generic company execs and that he falsely denied having meals paid for by company representatives ("The Pink Sheet" June 25, T&G-5). Seife's attorney, Hamilton Fox (D.C. firm of Sutherland, Asbill & Brennan) said Seife will seek a jury trial on the charges.
You may also be interested in...
The appointment of Belén Garijo as CEO of the German major from May next year is a small but significant step on the road to addressing gender inequality at the very top level of management in the world of big pharma.
The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.
Stada has named Yann Brun to become the group’s new head of global development, portfolio, regulatory and business development, replacing Robert Knerr. The move is the latest in a string of key appointments at Stada as the firm builds on a series of acquisitions and deals.